Neuropeptide G protein-coupled receptors as oncotargets

TW Moody, I Ramos-Alvarez, RT Jensen - Frontiers in Endocrinology, 2018 - frontiersin.org
Neuropeptide G protein-coupled receptors (GPCRs) are overexpressed on numerous
cancer cells. In a number of tumors, such as small cell lung cancer (SCLC), bombesin (BB) …

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1–molecular pathways

M Cakir, D Dworakowska… - Journal of cellular and …, 2010 - Wiley Online Library
Introduction• The somatostatin receptor as a GPCR• Anti‐tumour effects of somatostatin•
Post‐receptor signalling pathways‐Phosphotyrosine phosphatases and their action on …

Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin

CJ Auernhammer, B Göke - Gut, 2011 - gut.bmj.com
Multimodal treatment options for advanced gastroenteropancreatic neuroendocrine tumours
(NET) of jejunum/ileum and of pancreatic origin are reviewed. Current topics being …

[HTML][HTML] Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2–clinical implications

M Cakir, D Dworakowska… - Journal of cellular and …, 2010 - ncbi.nlm.nih.gov
• Conclusions 2586 reconsidered, it is also understandable that not always will these two
components go hand in hand in every tumour treated. There are GH-secreting pituitary …

Preclinical evaluation of Som230 as a radiation mitigator in a mouse model: postexposure time window and mechanisms of action

Q Fu, M Berbée, W Wang, M Boerma… - Radiation …, 2011 - meridian.allenpress.com
The somatostatin analog SOM230 has potent radioprophylactic and radiation mitigating
properties that are unrelated to cytoprotection but appear to be due to suppression of …

Neuroendocrine tumors: a critical appraisal of management strategies

AI Vinik, L Anthony, JP Boudreaux, VLW Go… - Pancreas, 2010 - journals.lww.com
Objectives: This supplement represents the proceedings of a panel of investigators whose
goal was to assess the quality of evidence pertaining to current therapeutic approaches in …

[PDF][PDF] Lanreotide treatment of metastatic hepatocellular carcinoma resulting in partial regression and more than 3 years of progression-free survival

I Borbath, R Lhommel, Y Guiot, E Coche… - Acta Gastro Enterol …, 2012 - dial.uclouvain.be
We describe the case of a 54 years old woman, with hepatitis B, in whom the diagnosis of a
6 cm hepatocellular carcinoma (HCC) in the left liver was made in 2001. Alpha-foeto-protein …

[PDF][PDF] Review of literature of clinical pancreatology

A Andren Sandberg, O Azodi - 2009 - pancreapedia.org
This is a compilation of the reports of the three first quarters of 2010 on what is written in the
scientific literature on pancreas. The main source has been PubMed, but also the Journals …

Lebermetastasierung bei neuroendokrinen Karzinomen des gastro-entero-pankreatischen Systems–Therapiestrategien

CJ Auernhammer, KW Jauch… - Zentralblatt für …, 2009 - thieme-connect.com
Neuroendokrine Tumoren (NET) unterscheiden sich bezüglich ihres biologischen
Verhaltens erheblich von Tumoren epithelialen Ursprungs, was im Allgemeinen eine …

[PDF][PDF] Management of pancreatic neuroendocrine neoplasms in “real life” at Cliniques Saint-Luc: analysis based on the Belgian DNET registry

G Brassel, I Borbath - dial.uclouvain.be
1.1 Abstract in english Background and Objectives: The management of pancreatic
neuroendocrine neoplasms (PNENs) is not well established especially for unresectable …